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In patients with aortic and/or mitral valve disease the presence of pulmonary hypertension 
(PH) indicates a decompensated state of the disease with left ventricular and left atrial 
dysfunction and exhausted compensatory mechanism, i.e., a state of heart failure. 
Pulmonary hypertension in this context is the consequence of the backwards transmission 
of elevated left atrial pressure. In this form of PH, pulmonary vascular resistance is initially 
normal (isolated post-capillary PH). Depending on the extent and chronicity of left atrial 
pressure elevation additional pulmonary vascular remodeling may occur (combined 
pre- and post-capillary PH). Mechanical interventions for the correction of valve disease 
often but not always reduce pulmonary pressures. However, the reduction in pulmonary 
pressures is often modest, and persistent PH in these patients is common and a marker 
of poor prognosis. In the present review we discuss the pathophysiology and clinical 
impact of PH in patients with aortic and mitral valve disease, the comprehensive non-
invasive and invasive diagnostic approach required to define treatment of PH, and recent 
insights from mechanistic studies, registries and randomized studies, and we provide an 
outlook regarding gaps in evidence, future clinical challenges, and research opportunities 
in this setting.
Keywords: pulmonary hypertension, post-capillary, pre-capillary, combined pre- and post-capillary, valve disease, 
aortic stenosis, mitral regurgitation
intRoDuction
In patients with left heart disease, the presence of pulmonary hypertension (PH) is an important feature 
as it represents a marker of more advanced disease and poor prognosis (1). Pulmonary hypertension 
due to left heart disease (group 2 PH) is the by far most common type of PH, and valve disease is the 
leading cause (2). Independent of symptoms the presence of PH in patients with valve disease indicates 
a decompensated state of the disease with left ventricular (LV) and left atrial (LA) dysfunction and 
exhausted compensatory mechanism, i.e., a state of chronic heart failure (HF) with a propensity for 
acute exacerbations, e.g., in the context of arrhythmia or volume challenges. In the present article, 
we review the epidemiology and pathophysiology of PH in aortic and mitral valve disease and the 
diagnostic and therapeutic approach in these patients, and we provide considerations regarding future 
clinical challenges and research opportunities in this setting.
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clAssificAtion
Pulmonary hypertension in patients with left-sided valve disease 
is a consequence of valve disease and its impact on LV and 
LA function respectively and belongs to group 2 PH (3, 4). By 
definition this PH group is characterized by a mean pulmonary 
artery pressure (PAP, mPAP) ≥25 mmHg and a mean pulmonary 
capillary wedge pressure (mPAWP) >15 mmHg (4). In Table 1, 
a simplified version of the current PH classification (4) with the 
position of group 2 PH and in particular PH in valve disease is 
provided. Notably, group 2 PH is the only post-capillary form of 
PH. As discussed below the PH subgroups 2.1 to 2.3. cannot not be 
separated completely when discussing PH in the context of valve 
disease. As also discussed below there are patients who have two 
disease entities, i.e., valve disease and a form of PH not related to 
valve disease (i.e., non-group 2 PH).
ePiDeMiology
The prevalence of PH in patients with aortic and mitral valve 
disease depends on the type and severity of valve disease, the 
associated LV and LA dysfunction as well as other patient 
characteristics including age and cardiac rhythm and the method 
of PAP assessment. Direct measurement of mPAP by right heart 
catheterization (RHC), which is required for an exact diagnosis of 
PH, was performed in the minority of studies. The majority of data 
on the prevalence and prognostic impact of PH in valve disease are 
derived from echocardiographic studies where systolic PAP (sPAP) 
was estimated based on the peak tricuspid regurgitation velocity 
(TRV) using the Bernoulli equation. Many studies in the context of 
valve disease have defined significant PH as a sPAP ≥50 (TRV≈3.5 
m/s) or ≥60 (TRV≈3.9 m/s) mmHg (Table  2). Independent of 
the presence or absence of additional echocardiographic signs of 
significant PH [such as right ventricular (RV) dilatation and/or 
dysfunction, D-shape of the left ventricle, shortened pulmonary 
acceleration time] these cut-offs are indicators of a high probability 
of PH and are associated with high specificity (4).
In Table 2, important contemporary studies on the prevalence 
of PH in aortic and mitral valve are summarized (5–35). In patients 
with mitral stenosis (MS), 30–40% of patients undergoing valve 
replacement or valvuloplasty have substantial PH (systolic PAP 
> 50–60 mmHg by echocardiography or mean PAP > 40 mmHg 
by RHC). In series of patients with moderate or severe mitral 
regurgitation (MR) undergoing valve surgery early after the echo 
or later during follow-up in the majority of cases, a prevalence of 
PH defined as sPAP >50 mmHg was found in 15–32% of patients. 
For patients with aortic regurgitation (AR) there is very little data. 
One study found a prevalence of 16% of PH defined as sPAP 60 ≥ 
mmHg in a cohort of patients with severe AR (35). In patients with 
AS the prevalence of PH is high, particularly in the elderly. Up to 
75% of patients with severe AS undergoing TAVR were found to 
have PH as assessed by RHC. In echo studies, the prevalence of 
sPAP >60 mmHg or ≥60 mmHg varied between 9 and 34%.
Mechanisms of PH in Aortic and Mitral 
valve Disease
With the exception of the relatively rare cases of patients with 
valve disease who have a second disease unrelated to valve 
disease and therefore do not have group 2 PH, the primary 
mechanism of elevated PAP in patients with left heart disease is 
the backward transmission of an elevated LA pressure (LAP) (3). 
The latter can be estimated by measurement of PAWP by RHC 
since direct access to the LA is not possible. It has to be realized 
however that there are some patients in whom PAWP does not 
reflect LAP: those with pulmonary veno-occlusive disease (high 
PAWP, normal LAP, obstruction of pulmonary venules) and 
those pulmonary vein stenosis (high PAWP, normal LAP). In MS 
and MR, valve disease has direct impact on the LA, whereas in 
aortic stenosis (AS) and AR the LA is affected indirectly by LV 
dysfunction. Many patients in whom criteria for severe AS, AR, 
or MR are clearly met, do not have an elevated PAWP however. 
The latter only occurs if the compensatory mechanism (LV and LA 
dilatation and function) are exhausted and/or if there is significant 
hypervolemia. Elevation of LAP is the result of LV systolic [reduced 
left ventricular ejection fraction (LVEF), reduced strain] and 
diastolic dysfunction (impaired relaxation and increased passive 
stiffness) and LA dysfunction (reduced compliance and booster 
function). Details of specific valve diseases are discussed below. 
A general principle however applies for the pathophysiology of 
PH in all types of left heart and left-sided valve diseases: initially 
PH is a purely passive phenomenon with a high LAP and PAWP 
but low transpulmonary gradient (difference between mPAP 
and mPAWP) and low pulmonary vascular resistance (quotient 
of transpulmonary gradient and cardiac output; isolated post-
capillary PH, IpcPH). However, recurrent and chronic LAP 
elevation can cause alveolar stress failure and eventually pulmonary 
vascular remodeling with the development of a pulmonary vascular 
component of PH as reflected by an elevation of transpulmonary 
gradient and pulmonary vascular resistance respectively (combined 
pre-capillary and post-capillary PH, CpcPH) (1, 36, 37). Little is 
known about the exact mechanisms underlying this process; it is 
tABle 1 |  Classification of pulmonary hypertension (PH) [according to Galie et 
al. (3)].
group Hemodynamic constellation
1 Pulmonary arterial hypertension Pre-capillary PH: mPAP ≥25 mmHg, 
mPAWP ≤15 mmHg
2 PH due to left-sided heart disease
2.1. Left ventricular systolic dysfunction
2.2. Left ventricular diastolic dysfunction
2.3. Valvular disease
2.4. Left heart inflow/outflow tract 
obstruction
2.5. Pulmonary vein stenosis
Post-capillary PH: mPAP ≥25 mmHg, 
mPAWP >15 mmHg
•	 Isolated post-capillary (IpcPH): PVR ≤3 WU
•	 Combined pre- and post-capillary (CpcPH): PVR 
>3 WU
3 PH due to lung disease and/or 
hypoxia
Pre-capillary PH: mPAP ≥25 mmHg, 
mPAWP ≤15 mmHg
4 chronic thromboembolic PH and 
other pulmonary artery obstructions
Pre-capillary PH: mPAP ≥25 mmHg, 
mPAWP ≤15 mmHg
5 PH associated with unclear and/or 
multifactorial mechanisms
Pre-capillary and post-capillary 
forms of PH
mPAP: mean pulmonary artery pressure, mPAWP: mean pulmonary artery wedge 
pressure, PVR: pulmonary vascular resistance (in Wood units, WU)
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tABle 2 |  Contemporary studies on the prevalence and prognostic impact of pulmonary hypertension (PH) in patients with aortic or mitral valve disease.
study Age 
(years)
severity of valve disease and 
setting
lvef (%) Af (%) Pulmonary artery pressure Main findings
Mitral stenosis (Ms)
Fawzy et al. (5) (n = 531) ≈31 Severe MS: mean diastolic 
gradient ≈ 14 mmHg
MVA≈0.8 cm2
Balloon valvuloplasty in all 
patients
N.A. ≈13 Echo sPAP >60 mmHg: 15% Worse 10 year event-free survival 
(redo valvuloplasty, mitral valve 
replacement) in patients with 
sPAP >60 mmHg than those 
with lower sPAP
Fawzy et al. (6) (n = 559) ≈31 Severe MS: mean diastolic 
gradient ≈ 15 mmHg
MVA≈0.8 cm2
Balloon valvuloplasty in all 
patients
N.A. N.A. RHC sPAP ≥50 mmHg: 38% Normalization of sPAP (Echo) in 
most patients after a follow-up 
4 years
Pourafkari et al. (7) (n = 558) 45 ± 13 Severe MS: Mean diastolic 
gradient 11 ± 6 mmHg, MVA 0.9 
± 0.1 cm2
Balloon valvuloplasty in all 
patients
≈52 ≈34 RHC or echo mPAP ≥25 mmHg: 
81%
Very high prevalence of PH
Yang et al. (8) (n = 317) 61 MS: no further information, but 
all patients undergoing mitral 
valve surgery
N.A. ≈47 RHC or Echo sPAP 45–59 
mmHg: 30% sPAP ≥60 mmHg: 
40%
Worse long-term survival in 
patients with sPAP ≥45 mmHg 
than those with lower sPAP
Mitral regurgitation (MR)
Ghoreishi et al. (9) (n = 873) 59 ± 14 Moderate (11%)
Moderate-severe (24%) oder 
severe (65%) MR
Mitral valve surgery in all patints
52 ± 14 30 RHC (68%) or echo (32%) sPAP 
≥50 mmHg: 32%
sPAP associated with operative 
and late mortality
Mentias et al. (10) (n = 1318) 62 ± 13 MR3+: ERO 0.56 ± 0.3 cm2
86% of patients undergoing 
valve surgery
62 ± 2 18 Echo sPAP >50 mmHg: 15% Prevalence of postoperative 
sPAP ≥35 mmHg: 19%
Association between sPAP and 
mortality after follow-up of 7.1 
years,
Barbieri et al. (11) (n = 437) 67 ± 11 MR (flail leaflet) grade 3–4: 95%
Mitral valve surgery in 75% of 
patients
64 ± 10 24 Echo sPAP >50 mmHg: 23% FU 4.8 years
PH as long-term predictor of 
death and heart failure; mitral 
valve surgery beneficial but PH 
predictor of perioperative death
Le Tourneau et al. (12) (n = 
256)
63 ± 12 MR grade 3 or 4 :
ERO 51 ± 19 mm2
Mitral valve repair or replacement 
in all patients
65 ± 10 29 Echo sPAP ≥50 mmHg : 32% sPAP as independent predictor 
of mortality after a follow-up 4.1 
years
Aortic stenosis (As)
Kusunose et al. (13) (n = 395) 70 ± 14 Moderate-severe or severe AS:
MVG 38 ± 18 mmHg
AVA 0.8 ± 0.2 cm2
59 ± 5 18 Echo sPAP 36 ± 11 mmHg Follow-up 4.4 years
No association between sPAP 
and mortality
Lucon et al. (14) (n = 2435) 83 ± 7 Severe AS:
MVG ≈48 mmHg
AVA ≈0.7 cm2
TAVR in 100% of patients
≈53 ≈30 Echo sPAP ≥60 mmHg: 20% Association between sPAP 40–
59 and ≥60 mmHg and mortality 
after follow-up of one year
Urena et al. (15)
(n = 3726)
81 ± 8 Severe AS:
MVG ≈47 ± 17 mmHg
TAVR in 100%
LVEF 
<40%:19%
30 sPAP >60 mmHg: 14% Association between sPAP >60 
mmHg and death due to heart 
failure after one year
Lindman et al. (16) (n = 542) ≈85 Severe AS:
MVG ≈45 mmHg, indexed AVA 
≈0.34 cm2/m2
TAVR in 100%
≈52 ≈37 Echo; sPAP ≈42 mmHg
RHC: mPAP≈28 mmHg
Association between moderate 
and severe TR and RV/RA 
dilation and death but no 
significant association between 
sPAP and mortality
Bishu et al. (17) (n = 251) 81 ± 8 Severe AS:
MVG 50 ± 13 mmHg
AVA ≈0.8 cm2
TAVR in 100% of patients
≈57 N.A. Echo sPAP ≥49 mmHg: 33% sPAP ≥49 mmHg associated 
with worse long-term mortality 
after median follow-up 328 days
O`Sullivan et al. (18) (n = 433) ≈83 Severe AS:
MVG ≈42 mmHg
AVA ≈0.6 cm2
TAVR in 100% of patients
≈52 ≈25 RHC mPAP ≥25 mmHg: 75% Follow-up 1 year
Association between precapillary 
and combined pre- and 
postcapillary PH and mortality
Continued
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study Age 
(years)
severity of valve disease and 
setting
lvef (%) Af (%) Pulmonary artery pressure Main findings
Généreux et al. (19) (n = 1661) ≈83 Severe AS: MVG ≈44 mmHg
AVA ≈0.7 cm2
SAVR or TAVR in 100% patients
LVEF <50%:
34%
40 Echo sPAP ≥60 mmHg; 27% Association between sPAP ≥60 
mmHg and/or moderate or 
severe TR and mortality after 
follow-up 1 year
Melby et al. (20) (n = 1080) ≈71 Significant AS (no further 
information)
SAVR in 100% of patients
≈49 ≈35 Echo or RHC sPAP ≥60 
mmHg:9%
Association between sPAP ≥35 
mmHg and higher mortality 
afterfollow-up 4 years
Better survival in those with 
pulmonary vascular resistance 
<3 WU than those with ≥3 WU
Nijenhuis et al. (21) (n = 591) 80 ± 8 Severe AS:
MVG≈42 mmHg, AVA≈0.75 cm2
TAVR in 100% of patients
≈55 39 Echo, probability of PH: low: 
46%
Intermediate: 22% high: 32%
High probability of PH as 
independent predictor of 30 days 
and 2 years mortality
Levy et al. (22) (n = 1019) 74 ± 11 Severe AS:
MVG = 46 (35-58)  mmHg,
AVA = 0.76 (0.61–0.90) cm2
75% with AVR (SAVR, TAVR)
63 (57–69) 31 Echo
Peak TRV >3.4 (46 mmHg): 11%
Peak TRV >3.4 m/s as 
independent predictor of 
mortality after a median follow-
up 31 months
Barbash et al. (23) (n = 415) 84 ± 8 Severe AS:
MVG ≈48 mmHg,
AVA ≈0.65 cm2
TAVR in 100% of patients
53 ≈42 Echo sPAP ≥50 mmHg: 59% Higher 30 day and one year 
mortality in patients with 
sPAP ≥50 mmHg sPAP as 
independent predictor of one 
year mortality
Magne et al. (24) (n = 749) 74 ± 8 Severe AS:
MVG: 48 ± 17 mmHg, AVA 0.69 
± 0.17 cm2
SAVR in 91% of patient
72 ± 10 14 RHC
mPAP >25 mmHg: 32% pre-
capillary PH: 8%
PH as independent predictor of 
30 day mortality and long-term 
mortality (mean follow-up 4.6 
years,)
Lindman et al. (25) (n = 2180) ≈84 Severe AS:
MVG ≈42 mmHg, indexed AVA≈ 
0.35 cm2/m2
TAVR in 100% of patients
≈55 NA RHC mPAP ≥25 mmHg: 64% Increased 1 year mortality in 
women with mPAP ≥35 mmHg, 
not in men
Franzone et al. (26) (n = 469) 82 ± 6 Severe AS:
MVG: 44 ± 17 mmHg, AVA 0.7 
± 0.2 cm2
TAVR in 100% of patients
54 ± 14 68 RHC mPAP = 48 ± 14 mmHg mPAP as predictor of two year 
mortality in univariate but not 
multivariate analysis
Cam et al. (27) (n = 317) ≈73 Severe AS:
AVA≈0.7 cm2
SAVR in 47% of patients
≈50 ≈30 RHC mPAP ≥25 mmHg: 47% Lower 30 day and long-term 
mortality (mean follow-up 548 
days
) in patients with mPAP >35 
mmHg undergoing SAVR versus 
those not undergoing surgery
Similar long-term mortality in 
patients with mPAP 25–35 
mmHg and those with mPAP 
>35 mmHg when undergoing 
SAVR
Sinning et al. (28) (n = 353) 81 ± 7 Severe AS:
MVG 42 ± 16 mmHg,
AVA 0.7 ± 0.2 cm2
TAVR in 100% of patients
48 ± 14 27 Echo: sPAP >60 mmHg: 26% Higher 30 days and 2 year 
mortality in patients with sPAP 
30–60 mmHg and sPAP >60 
mmHg
Worse prognosis in patients with 
persistent PH (sPAP >60 mmHg) 
after TAVR (Mean follow-up 517 
days)
Ben-Dor et al (29) (n = 509) ≈82 Severe AS
MVG ≈43 mmHg,
AVA ≈0.7 cm2
≈50 N.A. Echo
≥60 mmHg: 34%
Association between higher 
sPAP and higher mortality after 
median follow-up 202 days
Masri et al. (30) (n = 407) ≈83 Significant AS: MVG ≈48 mmHg,
AVA ≈0.6 cm2
TAVR in 100% of patients
≈55 46 RHC mPAP ≥25 mmHg: 67% Persistent at least moderate 
PH (Echo sPAP >45 mmHg) in 
25%, which was an independent 
predictor of mortality
tABle 2 |  continued
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suspected that similar mechanisms and mediators play a role as 
in the pathobiology of pulmonary arterial hypertension (36, 37). 
Recent post-mortem data from well characterized patients with 
HF with reduced LVEF (HFrEF) and HF with preserved LVEF 
(HFpEF] without significant underlying or associated valve disease 
have revealed that pulmonary vascular remodeling is global but that 
the hemodynamic severity of PH is primarily related to remodeling 
of pulmonary venules (38). Similarly to other forms of PH valve-
disease related PH can lead to RV dilatation and dysfunction and 
secondary tricuspid regurgitation but the clinical presentation can 
vary significantly (LV phenotype – the more common situation – 
versus RV phenotype) (36). In addition, we have to consider that 
the cardiac chambers and pulmonary circulation not only work 
in series (although we will in the following use such a schematic 
presentation) but that direct interactions on the ventricular and 
atrial level occur via septum. For instance, there is evidence from 
patients with MR that LV-RV interactions may play a role in the 
pathophysiology of RV dysfunction independently of PH (39).
DiAgnostic PRinciPles
In this paragraph, the general principles of the diagnostic approach 
are discussed, whereas the specific aspects for each valvular lesion 
are discussed below in the respective sections. The two basic 
questions in this context are the following ones: First, is PH present? 
Second, is the valve disease and consecutive cardiac dysfunction 
sufficient to explain the presence and extent of PH?
non-invasive estimation of PAP
The estimation of PAP by echocardiography in patients with valve 
disease follows the usual principles as outlined in current guidelines 
(4): the probability of PH (i.e., mean PAP ≥ 25 mmHg) is low if 
peak TRV is ≤2.8 m/s and there are no indirect echocardiographic 
signs of PH (such as RV dilatation and/or dysfunction, D-shape 
of the left ventricle, shortened pulmonary acceleration time). The 
probability of PH is intermediate if peak TRV is ≤2.8 m/s but there 
are indirect signs of PH or if peak TRV is 2.9–3.4 m/s but without 
indirect signs of PH. The probability of PH is high if peak TRV is 
2.9–3.4 m/s with indirect signs of PH or if peak TRV is ≥3.4 m/s 
regardless of indirect signs of PH. To be correct the central venous 
pressure as estimated from diameter and respiratory variability of 
the inferior vena cava has to be added to the transtricuspid pressure 
difference (as calculated from peak TRV) to calculate systolic PAP. 
However, this has not consistently been done in clinical studies, 
and even the current PH guidelines do not make absolutely clear 
how we should deal with this issue. An assessment of the RV and 
the tricuspid valve must be performed at the same time as RV 
function is an important prognostic predictor in various settings 
including left-sided valve disease (40).
Differential Diagnosis of PH
If there is non-invasive evidence of PH, the underlying mechanism 
has to be assessed by multimodal imaging with echocardiography 
again being the key tool. The key question always is whether there 
is post-capillary or pre-capillary PH. The first step to address this 
is to assess the severity of the stenosis or regurgitation of the aortic 
study Age 
(years)
severity of valve disease and 
setting
lvef (%) Af (%) Pulmonary artery pressure Main findings
Testa et al. (31) (n = 990) ≈81 Severe AS:
MVG ≈44 mmHg
TAVR in 100% of patients
≈52 23 Echo sPAP >60 mmHg: 22% Higher 1 year mortality in 
patients with baseline sPAP 
40–60 mmHg and sPAP >60 
mmHg
Post-TAVR sPAP >60 mmHg 
at one month as independent 
predictor of 1 year mortality
D’Ascenzo et al. (32) (n = 674) ≈81 Severe AS:
MVG ≈49 mmHg,
AVA ≈0.6 cm2
TAVR in 100% of patients
≈55 N.A. Echo sPAP >40 mmHg: 47% Higher 30 days and long-term 
(median follow-up 477 days) 
mortality in patients with sPAP 
>40 mmHG
Roselli et al. (33) (n = 2385) 74 ± 10 Severe AS:
MVG = 48 ± 16 mmHg,
AVA = 0.66 ± 0.14 cm2
SVAR in 100% of patients
53 ± 13 12 Echo sPAP >50 mmHg: 24% Higher in-hospital and long-
term (mean follow-up 4.3 years) 
mortality in patients with higher 
sPAP
Schewel et al. (34) (n = 439) 80 ± 7 Severe AS (no further details)
TAVR in 100% patients
53 ± 13 47 RHC mPAP ≥25 mmHg: 53% Higher 30 days and one year-
mortality in patents with mPAP 
≥25 mmHg
Aortic regurgitation (AR)
Khandhar et al. (35) (n = 506) ≈63 Severe AR ≈52 ≈33 Echo sPAP ≥60 mmHg: 16% 32/83 patients with sPAP ≥60 
mmHg undergoing surgery: 
better outcome than those not 
doing so
AF, atrial fibrillation, AVA: aortic valve area, AVR: aortic valve replacement, LVEF: left ventricular ejection fraction, mPAP: mean pulmonary artery pressure, MVA: mitral valve area, 
MVG: mean valvular gradient, NA: not available, RHC: right heart catheterization, sPAP: systolic pulmonary artery pressure, SVAR: surgical aortic valve replacement, TAVR: 
transcatheter aortic valve replacment, TRV: tricuspid regurgitant velocity.
tABle 2 |  continued
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and/or mitral valve. According to the current understanding of the 
grading of the severity of valve disease, only lesions fulfilling criteria 
for severe valve stenosis or regurgitation are hemodynamically 
significant in that they can cause LV dysfunction, LAP elevation 
and subsequently post-capillary PH. A description of the grading 
of AS/AR/MS/MR is beyond the scope of this review but can be 
found elsewhere(41). The next step is the assessment of LV systolic 
and diastolic function and semi-quantitative estimation of LVEDP 
and LAP (in relation to right atrial pressure) by echocardiography. 
If the severity of valve disease and LV dysfunction are likely to 
explain the presence and extent of PH, and the entire picture fits to 
a post-capillary form of PH, RHC can be deferred, treatment can be 
initiated, and a follow-up echocardiogram will help to understand 
whether the working hypothesis was appropriate (1, 36).
There will be situations however, where it remains unclear 
whether the presence and extent of PH is explained by the 
severity of valve disease. We will use in the following a diagram to 
present the various hemodynamic patterns in a simplified manner 
(Figure 1). The following scenarios have to be considered: a patient 
may have two diseases, i.e., either valve disease and non-group 2 PH 
(Figure 2) or valve disease and PH in the context of LV dysfunction 
which however is not primarily the result of valve disease (Figure 3) 
although valve disease can contribute to further progression of LV 
dysfunction. Examples for the latter include severely reduced LVEF 
due to non-ischemic cardiomyopathy and moderate secondary 
MR or moderately reduced LVEF after myocardial infarction and 
moderate AS. Echocardiography can help to distinguish between 
post-capillary (group 2 PH) and pre-capillary (non-group 2) forms 
of PH although this is not always reliable. A small or normal-sized 
left ventricle without hypertrophy, a high LV eccentricity index 
(i.e., a D-shaped LV), a larger right atrium than LA, and enlarged 
and apex-forming RV, a low peak early transmitral velocity to peak 
early mitral annular velocity (mitral E/e’), and a short pulmonary 
acceleration time are markers of pre-capillary rather than post-
capillary PH (1).
In Table 3, there is a summary of clinical features which should 
raise the suspicion of the presence of non-group 2 PH or group 2 PH 
which is not the result of valve disease, which should trigger a more 
extensive work-up.. In these situations it will often be important 
to perform RHC to clarify the situation. Left heart catheterization 
with measurement of LVEDP will sometimes be helpful or even 
compulsory to unequivocally define the hemodynamic pattern 
and to exclude rare pathologies such as veno-occlusive disease. By 
definition (4) if there is PH (mPAP ≥25 mmHg), mPAWP must be 
figuRe 1 |  Normal hemodynamic situation of the circulation from the right 
heart across the lung and the left heart. AV: aortic valve, CO2: carbon dioxide, 
LA: left atrium, LAP: left atrial pressure, LV: left ventricle, LVEDP: left 
ventricular enddiastolic pressure, mPAP: mean pulmonary artery pressure, 
mPAWP: mean pulmonary artery wedge pressure, MV: mitral valve, PA: 
pulmonary artery, PV: pulmonary veins, PVR: pulmonary vascular resistance, 
O2: oxygen, RV: right ventricle.
figuRe 2 |  Hemodynamics of pulmonary hypertension (PH) other than 
group 2 PH in a patient with non-severe mitral stenosis (MS), mitral 
regurgitation (MR), aortic stenosis (AS), or aortic regurgitation (AR). PAH: 
pulmonary arterial hypertension, CTEPH: chronic thromboembolic PH. 
* typically relatively low. Other abbreviations as in figure 1.
figuRe 3 |  Hemodynamics of group 2 pulmonary hypertension due to 
non-valve disease related left ventricular (LV) dysfunction in a patient with 
non-severe mitral stenosis (MS), mitral regurgitation (MR), aortic stenosis (AS), 
or aortic regurgitation (AR). Other abbreviations as in figure 1.
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≥15 mmHg, and LVEDP must be similar, if PH is the result of MR, 
AR or AS. If PH is the consequence significant MS, mPAWP ≥15 
mmHg and a significant diastolic PAWP-LV pressure gradient must 
be present. If mPAP is ≥25 mmHg but mPAWP is <15 mmHg, there 
is a non-group 2 PH. The presence of non-group 2 PH is relatively 
rare in patients with severe valve disease but its recognition is of 
paramount importance since in such a patient a mitral or aortic 
valve intervention will not lower pulmonary pressures. Having said 
that it is also well known that in some patients with longstanding 
CpcPH RHC may reveal pure pre-capillary PH after aggressive 
reduction of filling pressures by diuretics or and/or after valve 
replacement, and that only a volume challenge may reveal the true 
hemodynamic picture (42). In patients with severe valve disease 
and LV dysfunction likely to explain the presence of PH but non-
invasive evidence of disproportionally high PAP, RHC will be 
important to assess whether there is IpcPH or CpcPH as this has 
prognostic impact (18). The current valve disease guidelines are 
relatively reluctant with regards to RHC during the work-up of a 
patient with valve disease potentially undergoing valve surgery/
valve intervention (41). However, given the previous considerations 
we think that in patients evaluated/planned for valve surgery/
intervention RHC should be performed at the time of the coronary 
angiogram. In Figure 4, an algorithm for the use of RHC in the 
assessment of a patient with valve disease and possible PH is shown.
Role of exercise Hemodynamics
Although it is appealing to study PAP on exercise to discover the 
clinical relevance of valve disease in ambiguous situations (3, 
43), the role of exercise PH is not well defined at the moment. 
Stress echocardiography studies have shown that exercise PH 
(typically defined as systolic PAP > 60 mmHg) is associated with 
the future occurrence of symptoms in asymptomatic patients with 
at least moderate degenerative MR (44), cardiac events in patients 
with secondary MR (45), and cardiac events in asymptomatic 
patients with severe AS (46). However, exercise PAP depends on 
pulmonary blood flow, and an absolute exercise s PAP value has to 
be interpreted in the context of exercise capacity and pulmonary 
blood flow respectively (3). In addition, exercise sPAP has been 
shown to be strongly related to resting sPAP (44–46), and therefore 
the additional information of exercise PH is somewhat limited. 
Furthermore, stress echocardiography cannot reveal the exact 
mechanism underlying the rise in sPAP during exercise (rise in 
LAP versus rise in pulmonary vascular resistance). Recently, it 
has become clear that PH is common also in HFpEF in absence 
of significant valve disease (37, 47) and there may be a spectrum 
of hemodynamic rest/exercise profiles ranging from an isolated 
rise in PAWP during exercise to a CpcPH pattern with a rise in 
both PAWP and PVR during exercise (48). A similar diversity is 
likely present in patients with valve disease but data on invasive 
exercise hemodynamics in patients with valve disease are lacking. 
Thus, guidelines (41) currently do not provide recommendations 
for interventions based on exercise PH.
PH in specific valve Diseases
Mitral Stenosis
In patients with MS, the LV is not affected by the valvular 
problem although in rheumatic heart disease LV dysfunction 
can occur independently of valve disease. The obstruction at the 
level of the mitral valve leads to increased LAP which is directly 
backwards transmitted to the pulmonary veins (Figure 5) (3). 
The transmitral gradient is a strong but not the only determinant 
of PAP (49). Lower net atrioventricular compliance, a composite 
measure of LA and LV compliance, has been shown to be a 
predictor of sPAP independent of mitral valve area and mean 
diastolic pressure gradient (49). Notably, net atrioventricular 
compliance and mitral valve area have also been identified as 
independent predictors of valve intervention or death in patients 
with MS (49). The LA in severe MS is often significantly enlarged, 
and LA function is impaired due to fibrosis. This in turn can lead 
tABle 3 |  Clinical features in patients with valve disease and pulmonary hypertension (PH) suggesting the possibility of the presence of PH with a mechanism 
unrelated to valve disease; these considerations are particularly relevant if valve disease does not fulfil criteria for severe stenosis/regurgitation.
clinical context Possible mechanism of PH Diagnostic evaluation
PH and significant hypoxemia (in absence of frank 
pulmonary edema)
PH due to lung disease and/or hypoxemia (group 3 PH)Lung function, blood gas analysis, sleep studies, CT, 
right heart catheterization
PH and rheumatic disease (e.g., lupus erythematodes) Group 1 PH Rheumatology work-up, diffusion capacity, right heart 
catheterization
PH and non-severe valve disease in combination with 
normal LV size and function
Any non-group 2 PH Right and left heart catheterization, search for other 
forms of PH (lung function, sleep studies, V/Q scan, 
rheumatology work-up)
PH and non-severe valve disease in combination with 
significant LV dysfunction
Any group 2 PH which is not (only) a consequence 
of valve disease (e.g., ischemic cardiomyopathy with 
moderate secondary MR)
Detailed echocardiography, cardiac MRI, Holter 
monitoring, left and right heart catheterization
PH and non-severe valve disease in combination with 
preserved LVEF and history of thoracic radiation
Group 2 PH in the context of HFpEF following radiation 
(significant coronary artery disease may also be 
present)
Detailed echocardiography, left and right heart 
catheterization
PH and non-severe valve disease, history of catheter 
ablation for atrial fibrillation years ago
Pulmonary vein stenosis Left and right heart catheterization including 
measurement of LVEDP, CT
PH and non-severe valve disease, history of catheter 
ablation for atrial fibrillation years ago
Stiff left atrial syndrome Left and right heart catheterization including 
measurement of LVEDP, cardiac MRI
PH and previous thrombosis/pulmonary embolism, 
immobilization, cancer, coagulation disorder
Chronic thromboembolic pulmonary hypertension 
(Group 4 PH)
V/Q scan, right heart catheterization
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to atrial fibrillation which can further aggravate LA dilation and 
dysfunction.
Chronic LAP elevation can lead to pulmonary vascular 
remodeling and additional pre-capillary PH, and patients with long-
standing severe MS often have substantial CpcPH. In a large study 
using RHC (n = 599), 38% of patients with severe MS undergoing 
percutaneous mitral commissurotomy had sPAP ≥50 mmHg. Many 
of these patients had CpcPH [mean PVR 329 dyn*sec*cm−5 (4.1 
WU) and 857 dyn*sec*cm−5 (10.7 WU) in patients with sPAP 50–79 
and ≥80 mmHg respectively] (6). This increase in RV afterload can 
lead to RV dilatation and dysfunction with secondary tricuspid 
regurgitation which can be further aggravated by structural 
alterations of the tricuspid valve in rheumatic heart disease. Studies 
have shown that significant pre-intervention PH is a predictor of 
poor long-term prognosis in patients with severe MS undergoing 
valve replacement or percutaneous mitral commissurotomy (5, 8). 
Isolated post-capillary PH usually resolves quickly after successful 
mitral valve intervention, whereas in patients with CpcPH, PH can 
persist despite normalization of LAP and PAWP, and paradoxically 
hemodynamics in such patients may reveal pure pre-capillary PH 
years after mitral valve intervention. Thus, incomplete resolution 
of PH with persistence of pre-capillary PH and RV dysfunction 
in patients with long-standing PH are the most likely mechanism 
underlying the prognostic value of PH in MS although one study 
has shown normalization of PH in all patients with PH even in 
those with baseline systolic PAP > 80 mmHg (6). The current 
ESC guidelines acknowledge the role of PH as a marker of more 
advanced disease and give a IIa recommendation for percutaneous 
mitral commissurotomy in patients with significant MS (valve area 
<1.5 cm2), no/little symptoms but a systolic PAP > 50 mmHg (41).
Mitral Regurgitation
Primary Mitral Regurgitation
The LV volume overload in chronic severe degenerative MR 
leads to progressive LV dilatation and eccentric hypertrophy and 
figuRe 4 |  Suggested algorithm to detect pulmonary hypertension (PH) using echocardiography (echo) and right heart catheterization (RHC) in patients with 
left-sided valve disease (VD, i.e., mitral stenosis and/or regurgitation, aortic stenosis and/or regurgitation). 1low probability of PH: peak TRV ≤2.8 m/s and no indirect 
echocardiographic signs of PH 2intermediate probability of PH: peak TRV ≤2.8 m/s but indirect signs of PH or if peak TRV but without indirect signs of PH, high 
probability of PH: peak TRV 2.9–3.4 m/s with indirect signs of PH or peak TRV ≥3.4 m/s regardless of indirect signs of PH 3please see figure 3.
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eventually systolic and diastolic dysfunction. This together with 
the direct effect of the systolic backflow into the LA under LV 
pressure can lead to LAP elevation with large V waves and PAWP 
elevation (Figure 6). The LV in severe primary MS is that of a 
special form of heart failure with preserved, midrange, or reduced 
LVEF. The ventricle is dilated, and as soon as LVEF is <60% there is 
systolic dysfunction which however is masked by the high preload 
(50). Any LVEF less than 60% in patients with degenerative MR 
is associated with reduced survival under medical therapy (51). 
Systolic LV dysfunction in MR is accompanied by increased 
LV stiffness, i.e., diastolic dysfunction. Left atrial enlargement 
is the result of LV dysfunction and volume overload and favors 
the occurrence of atrial fibrillation (52). Larger LA size in severe 
MR is associated with higher PAP and worse outcome (53). 
Independent predictors of higher sPAP in three studies included 
higher age (11), female sex (10), larger LA size (10–12), larger 
LV end-systolic dimensions (10), higher medial E/e’ (12), shorter 
mitral deceleration time (12) chronic lung disease (10), dialysis 
(10), previous myocardial infarction (10), and higher body mass 
index (10). In all large contemporary series of patients with MR 
with the majority undergoing surgery, baseline sPAP as assessed 
by echocardiography (3 studies) or RHC or echocardiography (one 
study) was a strong predictor of mortality (9–12).
Notably, despite successful mitral valve surgery, PH may 
persist. In a series of 1318 patients with degenerative MR with 86% 
undergoing mitral valve surgery, postoperative sPAP >35 mmHg 
was observed in 19% of patients and was predicted by older age 
and higher preoperative sPAP (10). In another large series (n = 
873) of patients undergoing surgery for MR the sPAP in the entire 
population decreased from 43 mmHg before surgery to 39 mmHg 
early after surgery and remained unchanged after two years (9).
Both the 2017 ESC guidelines (41) and the 2017 update of 
the US guidelines (54) give a class IIa indication for surgery for 
asymptomatic patients with LVEF >60%, and LVESD <45 mm 
(i.e., no indication for surgery based on LV remodeling) but the 
presence of PH defined as sPAP >50 mmHg. Guidelines explicitly 
mentioned that an sPAP >50 mmHg should be confirmed by RHC 
if this represents the sole criterion for surgery (41).
Secondary Mitral Regurgitation
In contrast to primary MR the mitral valve in secondary 
(or functional) MR is initially structurally normal, and LV 
dysfunction is initially the result of a process unrelated to the 
mitral valve (e.g., myocardial infarction with LV remodeling) 
which then leads to MR. Thus, PAWP elevation and post-
capillary PH in patients with secondary MR may be result of 
LV dysfunction per se, MR, and the secondary effects of MR on 
the ventricle (MR begets MR). In patients with LV dysfunction 
(LVEF <50%), the severity of secondary MR was identified 
as an independent predictor of higher sPAP (55). However, 
a more recent study showed similar mPAP and mPAWP in 
patients with advanced HFrEF (median LVEF 27%) with no/
mild, moderate, or severe secondary MR (56) clearly indicating 
that MR in this setting is not the only driver of PH. On the 
other hand, the presence of PH (defined as sPAP ≥45 mmHg by 
echocardiography) has been shown to be a predictor of death 
in patients with LVEF ≤40%, but this association between PH 
and mortality was independent of LVEF, LV diastolic function, 
and functional MR (57) suggesting a complex pathophysiology 
of PH in this setting. Although detailed RHC data from a larger 
population of patients with secondary MR is not available, it 
is likely that many HFrEF patients with moderate or severe 
secondary MR and PH have CpcPH rather than simply IpcPH, 
and that the presence of a pre-capillary component of PH is the 
mediator of a poor prognosis and the incomplete response or 
absence of response to a mechanical intervention for MR. This 
assumption is supported by an important study by Dupont et 
al. (58) who demonstrated that in patients with HF [n = 724, 
mainly HFrEF (LVEF 19–9%)], low (inframedian) pulmonary 
capacitance (i.e., a parameter reflecting both high PAWP and 
figuRe 5 |  Hemodynamics of severe mitral stenosis (MS). It should be 
noted that the LV is not affected by the valvular problem, and LVEDP is 
normal. A significant diastolic gradient between LVEDP and PAWP is 
characteristic. Abbreviations as in figure 1.
figuRe 6 |  Hemodynamics of severe primary mitral regurgitation (MR). 
There is volume overload and dilatation of the both LV and LA. Abbreviations 
as in figure 1.
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high PVR) was associated with poor outcomes. Among the 
patients with low pulmonary capacitance (n = 362, mPAP = 37 
± 9 mmHg, mPAWP = 25 ± 7 mmHg), the prevalence of MR 
≥3 + was 43% indicating that there were many patients with 
secondary MR and CpcPH (58).
A variety of cardiac diseases can be associated with secondary 
MR. The pathophysiology is therefore variable and can include only 
moderately dilated LV’s with distorted geometry after an infarct 
in the territory of right or circumflex artery with tethering of one 
leaflet and eccentric MR or severely dilated LVs in the context of 
non-ischemic cardiomyopathy with severe annulus dilatation and 
tethering of the valve leaflets. As a consequence the mitral valve 
is not the primary target for therapy in patients with secondary 
MR and PH. The general approach in these patients is to treat 
the underlying cardiac disease in an optimal manner.Surgery or 
interventions for the correction of MR remain an option only for 
patients remaining symptomatic despite optimal medical and 
device therapy (41). Percutaneous mitral valve repair in secondary 
MR has been show to lead to an acute reduction in LAP, mPAWP, 
and mPAP. However, the baseline mPAP in that study was only 
mildly elevated (mPAP 29 mmHg), and the reduction of mPAP was 
relatively modest (- 3 mmHg) (59). In patients with more severe PH 
(sPAP >50 mmHg) in the context of secondary MR, percutaneous 
mitral valve repair has been shown to lead to a reduction in sPAP, 
but sPAP remained higher than in patients without baseline PH, 
and patients with pre-existing PH had a nearly four-fold higher 
mortality than patients without (60). In the German Transcatheter 
Mitral Valve Intervention registry (with two thirds of patients 
having secondary MR), percutaneous mitral valve repair was 
associated with a reduction in sPAP from pre-intervention to 
hospital discharge in patients with sPAP 37–50 mmHg (from 44 
to 40 mmHg) and those with sPAP >50 mmHg (from 60 to 51 
mmHg) (61). However, there was obviously persisting PH in many 
patients, and mortality in these two PH groups after percutaneous 
mitral valve repair was still higher than in those without PH (sPAP 
≤36 mmHg) (61). Registry data suggest that there is also some 
reverse LV and LA remodeling after percutaneous mitral valve 
repair in patients with secondary MR (62). However, the impact 
of this phenomenon on PH is unknown.
Given the various determinants of PH in patients with 
secondary MR and lack of data from controlled studies on the 
prognostic impact of mitral valve interventions in these patients, 
current guidelines (41) do not give recommendation regarding 
valve interventions based on the presence of PH in these patients.
Aortic stenosis
In severe AS, pressure overload leads to compensatory concentric 
LV hypertrophy. According to the Laplace equation (LV wall 
stress ~LV pressure * LV radius/LV wall thickness) an increase 
in wall thickness in presence of increased LV pressure helps to 
normalize wall stress. By this mechanism, many patients with 
severe AS can preserve their stroke volume, i.e., they have a stroke 
volume index >35 ml/m2 and a mean transvalvular gradient >40 
mmHg, i.e., high gradient severe AS. However, the process of the 
development of LV hypertrophy is maladaptive as it is associated 
with myocardial fibrosis and LV diastolic dysfunction with an 
increase in LVEDP to achieve a normal LV end-diastolic volume 
and finally an increase in LAP to ensure LV filling (Figure 7) 
(63). Thus, in AS with preserved LVEF which represents the vast 
majority of patients (Table 2), we are faced with a phenotype of 
HF which is very similar to that seen in patients with HFpEF 
in whom longstanding hypertension leads to concentric LV 
remodeling/hypertrophy, diastolic and systolic dysfunction as 
well as LA dysfunction (64, 65) resulting in a rise in PAWP and 
PAP already at rest (66) or on exercise (67). Similarly to HFpEF, 
patients with severe AS can have a spectrum of abnormalities in 
LV systolic function despite LVEF >50%, and in subset of patients 
with severe AS and LVEF >50%, stroke volume index is less 
than 35 ml/m2 due to impaired filling and contractility, an entity 
referred to as paradoxical low flow-low gradient severe AS (68).
As shown in Table 2, PH is common in patients with severe 
AS. In general there is an association between higher sPAP and 
more severe AS as expressed by lower aortic valve area (AVA) 
(14, 28) and lower LVEF (14, 28, 35). However, PH is common 
also in patients with normal or only mildly reduced LVEF, where 
LV diastolic dysfunction (17), LA dilatation (23, 28, 35) and 
dysfunction (69), atrial fibrillation (14), concomitant MR (14, 
23) and comorbidities including lung disease (17), obesity (27), 
anemia (27), and renal failure (27) are key determinants of PH. 
The majority of studies used echocardiography to assess the 
presence of PH, and thus the exact hemodynamics c remain 
unknown. In an interesting RHC study, O’Sullivan et al. (18) 
found that PH (invasive mPAP ≥25 mmHg) was present in 75% 
of elderly patients undergoing TAVR, 17% of whom had pre-
capillary PH and 83% had post-capillary PH (LVEDP >15 mmHg 
versus ≤15 mmHg was used for the definition since PAWP was 
not measured systematically). In the post-capillary PH group, 
82% had IpcPH and 18% had CpcPH. Patients with CpCPH had 
the smallest AVA, the lowest LVEF and the most severe MR.
As shown in Table  2, the vast majority of studies among 
patients with severe AS undergoing surgical aortic valve 
replacement (AVR, SAVR) or transcatheter AVR (TAVR) concur 
figuRe 7 |  Hemodynamics of severe aortic stenosis (AS). There is pressure 
overload of the LV with concentric hypertrophy. The LA is secondarily affected 
by diastolic and systolic LV dysfunction. Abbreviations as in figure 1.
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that the presence of pre-AVR PH is a predictor of death. A meta-
analysis summarizing the data from 16 TAVR studies showed an 
increased 30 day, 1 year, and 2 year mortality in patients with PH 
before TAVR (70). The analysis by O’Sullivan et al. (18) revealed 
that pre-capillary and CpcPH but not IpcPH PH were associated 
with increased 1 year mortality.
Studies concur that SAVR and TAVR reduced PAP in many 
but not all patients (18, 20, 28, 29, 31), and that the reduction 
in PAP is overall relatively modest. In the study by O’Sullivan 
(18), a reduction in sPAP (measured by echocardiography pre- 
and post-TAVR) following TAVR was observed in patients with 
IpcPH (50 to 45 mmHg) and CpcPH (58 to 50 mmHg) PH but 
not in those with pre-capillary PH (49 to 52 mmHg). The latter is 
not surprising, and the former is not unexpected either, because 
PH is the result of the maladaptive changes of the LV and LA 
in response to pressure overload and only in part due to AS 
per se, and removal of the outflow tract obstruction will not 
cure the LV disease immediately. A further reduction in PAP 
over time due regression of LV hypertrophy, LV dysfunction 
and LA dysfunction following relief of pressure overload may 
be expected. However, in one study sPAP remained unchanged 
from one week to one year after TAVR (27), and the same has 
been shown for patients after SVAR. Similarly, Sinning at al. 
(26) found a significant but limited reduction in sPAP three 
months after TVR in patients with baseline sPAP 30–60 mmHg 
(from 39 to 34 mmHg) and those with baseline sPAP ≥60 mmHg 
(from 66 to 50 mmHg). The extent of PAP reduction after SAVR/
TAVR is clinically important since several studies have shown 
that persistent PH after TAVR determines prognosis, and that 
the impact of post-TAVR sPAP is even more important than that 
of pre-TAVR systolic PAP (14, 28). In the study by Masri et al. 
(28), 67% of a cohort of 407 patients with severe AS undergoing 
TAVR had PH at baseline (mPAP ≥25 mmHg on RHC), and 
25% of the entire cohort had post-TAVR sPAP >45 mmHg on 
echocardiography, and these patients had a two-fold higher 2 
year mortality than patients without baseline PH and those 
with baseline PH but post-TAVR sPAP <45 mmHg. Baseline 
determinants of post-TAVR sPAP >45 mmHg included at least 
moderate MR, atrial fibrillation/flutter, more advanced LV 
diastolic dysfunction, and larger LA volume index.
Some studies have shown an early improvement of LV 
relaxation (71, 72) and LA reservoir and conduit function (72) 
after TAVR, and at least one study has revealed an improvement 
in peak atrial longitudinal strain and a reduction in LA volumes 
three months after TAVR (73). However, data on the effect of 
TAVR on LV relaxation (mediating the early and active phase 
of mitral inflow; e’) are controversial (72, 73), and even more 
importantly the process of recovery of LV stiffness (mediating 
the late and passive phase of mitral inflow) following AVR 
is very slow and often incomplete [recently summarized by 
Kampaktsis et a. (63)]. The presence of myocardial fibrosis is 
the probably key driver of increased LV stiffness and increased 
LAP and PH, which may explain the persistence of PH in many 
patients after AVR. Recent research has shown that the presence 
of any late gadolinium enhancement (marker of fibrosis) in 
cardiac MRI predicts mortality after AVR (74). Importantly, 
myocardial fibrosis in patients with AS is not uniform (75), 
and the pattern of myocardial fibrosis (extracellular volume 
expansion versus replacement fibrosis) is clinically relevant 
(76).
The 2017 ESC guidelines give a IIa indication for AVR 
in asymptomatic patients with severe AS without another 
indication for surgery but sPAP >60 mmHg (41). The guidelines 
state that PH should be confirmed by RHC if PH represents to 
only indication for surgery (41). Notably, this represents a very 
advanced stage of the disease with significantly worse prognosis 
than severe AS without PH (19) and low likelihood of complete 
recovery of LV diastolic and resolution of PH.
Aortic Regurgitation
Aortic regurgitation imposes combined volume and pressure 
overload (as indicated by an increased systolic wall stress) (77) 
to the LV resulting in LV dilatation, eccentric LV hypertrophy, 
and eventually LV dysfunction. In advanced stages, systolic and 
diastolic LV dysfunction, LA dysfunction, and secondary MR can 
lead to increased LAP and post-capillary PH (Figure 8). Markers 
of this remodeling process (LV end-systolic volume index >25 
mm/m2, LVEF <50%) are traditionally used as indications for 
surgery in asymptomatic patients (41). In contrast to patients 
with AS, there is little information on the prevalence and 
prognostic role of PH in patients with AR.
In one large contemporary series, 16% of patients with 
severe AR had sPAP ≥60 mmHg. These patients had larger LV 
dimensions, lower LVEF, and more severe MR than those with 
sPAP <60 mmHg (33). Magne et al. (3) reported mild PH (mPAP 
26–35 mmHg) in 23%, moderate PH (mPAP 36–45 mmHg) 
in 9%, and severe PH (mPAP >45 mmHg) in 5% of patients 
with various degrees of AR (no details published). In current 
guidelines (41), the presence of PH is not listed as a criterion 
for valve replacement in AR given the relative paucity of data 
on the subject.
figuRe 8 |  Hemodynamics of severe aortic regurgitation (AS). There is 
volume overload and dilatation of the LV. The LA is secondarily affected by 
diastolic and systolic LV dysfunction. Abbreviations as in figure 1.
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combined valve Disease
The combination of several valve lesion is not uncommon 
the most typical combination being that of AS and MR. The 
assessment of the severity of AS and MR in this situation is 
notoriously difficult because MR may lead to a reduction in 
forward stroke volume and thereby a low flow-low gradient AS 
situation with all its diagnostic challenges. On the other hand 
the increased LV afterload due to AS may lead to a reduction of 
forward stroke volume and an increase in MR respectively. In this 
context MR is often secondary but primary MR is also possible. 
Given the detailed discussion above the presence of PH is likely 
to be common in patients with both relevant AS and relevant 
MR, and pulmonary pressure may vary depending on filling 
status, ischemia and dynamic exacerbation of secondary MR, 
and cardiac rhythm (paroxysmal atrial fibrillation). A detailed 
discussion of combined valve disease is beyond the scope of 
the present article. To illustrate the complexity of PH in the 
context of combined valve disease we just want to mention the 
study by Toggweiler et al. (78) who have shown that in patients 
with severe AS undergoing TAVR, concomitant moderate or 
severe MR at baseline improved in 55% of patients. Predictors 
of MR improvement included the presence of secondary MR, 
absence of atrial fibrillation, and absence of PH (defined as 
systolic PAP > 60 mmHg as assessed by echocardiography or 
RHC). Thus, PH is clinically highly relevant also in this context 
although the mechanism underlying this observation is not easy 
to understand. It may be speculated that RV-LV interactions in 
presence of significant PH prevent improvements in LV geometry 
and MR.
clinical implications and future Directions
The presence of PH is common in valve disease, and most often 
the mechanism is IpcPH or CpcPH. Thus, PH in valve disease is 
a marker of HF highlighting that PH is indeed a very important 
parameter during the assessment and follow-up of patients with 
valve disease. As discussed above PH is the result of maladaptive 
changes to the LV, LA, and finally pulmonary vasculature and 
even the right heart, and these changes may persist fully or in 
a reduced form after valve intervention resulting in persistent 
PH with serious prognostic implications. As discussed above 
the hemodynamic results of valve interventions have mainly 
been observed by echocardiography. Given the complexity of the 
hemodynamic pattern and the importance of CpcPH in these 
patients, systematic RHC early and late after valve interventions 
may help to better understand their full effects. For instance, we 
know that aggressive left ventricular unloading by assist device 
implantation in patients with severe HF and severe CpcPH can 
reduce not only PAWP but also pulmonary vascular resistance 
(79).
The replacement or reconstruction of the valve is only one 
part of the therapy, and a potential residual cardiac dysfunction 
has to be treated as well. However, the latter aspect of has not 
been in the focus of research and clinical work in the last 
years but is only now being recognized. In the patients with a 
HFrEF phenotype after valve reconstruction or replacement it 
is relatively evident that standard HFrEF therapies (80) should 
be established, i.e., angiotensin converting enzyme inhibitors/
angiotensin receptor blockers, betablockers, mineralocorticoid 
receptor blockers, sacubitril/valsartan, ivabradine, and cardiac 
resynchronization although the effectiveness of these treatments 
in this context has not explicitly been proven. In patients with 
a HFpEF phenotype treatment is unknown (80). Given the 
similarities between HFpEF in the true sense and post-AVR 
HFpEF spironolactone may be the most attractive drug (81, 
82) although this is not proven either. In a substantial number 
of patients a pre-capillary component of PH may persist after 
valve replacement although systematic invasive studies in this 
particular setting are not available. Intense research in the field 
of PH in the context of HFrEF and HFpEF has revealed that a 
variety of complex mechanisms are involved in the pathogenesis 
of CpcPH in these patients, and that specific therapies with 
proven benefit in group 1 PH may not be efficient in these 
patients (1). Very recently, the first randomized trial assessing 
the effect of the 5-phosphodiesterase inhibitor sildenafil on 
symptoms and cardiac events in patients with persistent PH 
several months after valve replacement/repair has been published 
(mPAP ≥30 mmHg required for inclusion; median mean PAP 
39 mmHg, median mPAWP 23 mmHg, median pulmonary 
vascular resistance 3.4 WU) (83). Interestingly, sildenafil therapy 
was associated with worse clinical outcomes (death, hospital 
admission, worsening functional class, global symptom burden) 
than placebo without differences between patient with normal 
or elevated pulmonary vascular resistance potentially indicating 
that specific PAH therapies may not be useful for the treatment 
post-valve replacement IpcPH and CpcPH. This result is very 
similar to than seen for sildenafil for the treatment of PH (IpcPH 
and CpcPH) in the context of HFpEF (66).
Given that an exponentially rising number of procedures 
for valve disease are now being performed also in very sick 
patients which will improve their symptoms and overall 
cardiac dysfunction to a certain degree and prevent death due 
to progressive pump failure, we will be faced with an increasing 
population of old and sick patients with post-valve replacement/
reconstruction heart failure and PH. Thus, intense research in 
the pathophysiology and the device and medical management 
of these patients is urgently needed.
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